Liang Y, et al. - Researchers investigated the link between serum phospholipase A2 receptor antibody (sPLA2R-ab) and clinical remission in patients with primary membranous nephropathy (PMN), via this meta-analysis of 11 clinical trials with 824 patients. These trials were identified via a systematic search of the literature. They observed a poor clinical remission rate, a higher titer of sPLA2R-ab, a lower likelihood of clinical remission, and a higher risk of renal failure, with no influence on relapse, in patients with positive sPLA2R-ab. For current guidelines, further evidence was generated that demonstrates the action of sPLA2R-ab as a diagnostic marker as well as a crucial predictor for clinical remission. Thus, sPLA2R-ab can be regarded as a prognostic factor for stratifying PMN patients.